Journal
IMMUNOLOGICAL REVIEWS
Volume 264, Issue 1, Pages 167-181Publisher
WILEY
DOI: 10.1111/imr.12276
Keywords
tuberculosis; immunity; antibodies; immunoglobulins; B lymphocytes
Categories
Funding
- National Institute of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) [AI-096213, AI-063537, AI-094745, AI-033774, AI-052733, AI-033142]
- National Heart, Lung, and Blood Institute (NHLBI) [HL-059842]
- Center for AIDS Research (CFAR) at the Albert Einstein College of Medicine [AI-51519]
- Aeras TB vaccine foundation
- Food and Drug Administration (FDA) [1U18 FD004012/01]
- Bill & Melinda Gates Grand Challenge award
- TB Vaccine Accelerator Program award
Ask authors/readers for more resources
Better understanding of the immunological components and their interactions necessary to prevent or control Mycobacterium tuberculosis (Mtb) infection in humans is critical for tuberculosis (TB) vaccine development strategies. Although the contributory role of humoral immunity in the protection against Mtb infection and disease is less defined than the role of T cells, it has been well-established for many other intracellular pathogens. Here we update and discuss the increasing evidence and the mechanisms of B cells and antibodies in the defense against Mtb infection. We posit that B cells and antibodies have a variety of potential protective roles at each stage of Mtb infection and postulate that such roles should be considered in the development strategies for TB vaccines and other immune-based interventions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available